FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors. Duke ES, Bradford D, Marcovitz M, Amatya AK, et al. Clin Cancer Res 2023;29:3573-3578.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Duke ES, Bradford D, Marcovitz M, Amatya AK, et al. FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors. Clin Cancer Res 2023;29:3573-3578.
PMID: 37265412